Cef-3 DS

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cef-3 DS

Cef-3 DS is a prescription-only medicine whose fundamental identity is defined by its active pharmaceutical ingredient, Cefixime. This medicinal entity is designated as an antibiotic and serves the essential purpose of eradicating susceptible bacterial pathogens responsible for systemic infections. As a synthetic compound, Cefixime belongs to the β-Lactam family, distinguishing it as a powerful third-generation agent designed for targeted antimicrobial action.

Quick Facts Description
Active ingredient Cefixime
Form Oral Suspension (DS), Tablet
Pharmacological class Third-generation cephalosporin
Common purpose Eradication of bacterial pathogens
Origin Semi-synthetic

What Type of Medicine is Cef-3 DS? (Identity and Classification)

Cef-3 DS is a third-generation cephalosporin antibiotic, a specialized classification within the larger β-Lactam group of antimicrobial agents. The active substance, Cefixime (C16H15N5O7S2), is a semi-synthetic compound developed to target a wide spectrum of bacteria. Cefixime functions by stopping the growth of bacteria, which interrupts bacterial proliferation in the body. This designation as a third-generation agent is clinically recognized for providing enhanced effectiveness against various bacteria, setting it apart from earlier-generation cephalosporin antibiotics. Its primary function is to eliminate the infectious agent, serving as a core component in the resolution of bacterial illnesses, such as management of acute uncomplicated infections.


Composition and Physical Form of Cef-3 DS

The medication is a single-ingredient product, containing only Cefixime as the therapeutic agent. Cef-3 DS is most frequently supplied for oral administration in two main dosage forms: an Oral Suspension (often commercially labeled as Dry Syrup (DS)) and a Tablet. The designation DS highlights a unique feature: it is specifically formulated as a powder that must be reconstituted with an aqueous vehicle (water) before use, providing a liquid format that is often preferred for pediatric patients or individuals who have difficulty swallowing solid tablets. Cefixime is designated as a broad-spectrum antibiotic used orally against susceptible infections. This pharmacological profile makes the drug an effective, orally administered solution for widespread use, particularly benefiting younger patient groups due to its ease of administration.


What is the General Purpose of Cefixime? (High-Level Function)

The general purpose of Cefixime is to achieve bactericidal activity, meaning it acts by actively killing the bacteria causing the infection. It fulfills this purpose by interfering with the synthesis of the essential peptidoglycan layer that forms the bacterial cell wall, which is a crucial structural component for the pathogen's survival. This destructive action occurs with a rapid onset against susceptible organisms. This precise mechanism of destruction provides the general benefit of halting the infectious process and resolving the condition caused by the susceptible microorganisms, making it a reliable therapeutic tool against bacterial pathogens.

Regulatory References

  1. MedlinePlus, affirms that Cefixime functions by stopping the growth of bacteria

What side effects are possible with Cef-3 DS?

Possible Side Effects and Safety Information

Cef-3 DS (cefixime) is generally well tolerated, with the most commonly reported adverse reactions being mild and self-limiting gastrointestinal effects. Safety information is summarized based on regulatory documentation.

Adverse Reactions

System Organ Class Common Reactions (Frequency ge 2%) Serious/Clinically Significant Reactions
Gastrointestinal Diarrhea (most frequent), nausea, loose stools, abdominal pain, dyspepsia, vomiting. Clostridium difficile-Associated Diarrhea (CDAD) and pseudomembranous colitis (may occur during or after therapy).
Immune/Skin Rash, pruritus (itching). Anaphylactic/anaphylactoid reactions (including shock and fatalities), Severe cutaneous reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis).
Hemic & Lymphatic Transient changes (e.g., eosinophilia). Agranulocytosis, pancytopenia, prolongation of prothrombin time, hemorrhage.
Renal/CNS Headache, dizziness. Acute renal failure, seizures (particularly in patients with renal impairment and inadequate dose adjustment).
Hepatic Transient elevation in liver enzymes (SGPT/SGOT). Hepatitis, jaundice.

Safety Restrictions and Monitoring

  • Contraindications: Use is strictly contraindicated in patients with known hypersensitivity to cefixime or any other cephalosporin antibiotics.
  • Cross-Sensitivity: Caution is required in patients with a history of penicillin allergy due to documented cross-sensitivity among beta-lactam antibiotics.
  • Renal Impairment: Dosage adjustment is necessary for patients with markedly impaired renal function to mitigate the risk of serious adverse effects like seizures.
  • Coagulation Risk: Coagulation effects, including increased prothrombin time, have been reported; this requires monitoring, especially in patients concomitantly receiving anticoagulants (e.g., warfarin). The chewable formulation may contain phenylalanine and is a consideration for patients with Phenylketonuria (PKU).

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the overdose profile for Cef-3 DS (Cefixime) by specifically documenting manifestations in the central nervous system. The most significant documented risk is encephalopathy, a condition which may include symptoms such as confusion, impairment of consciousness, movement disorders, and convulsions (seizures). Patients with underlying renal impairment are officially noted to be predisposed to this neurotoxicity risk in the event of an overdose, and acute renal failure is a possible severe outcome.

Manifestations and Risks Official Management Statements
Primary Risk: Encephalopathy, Seizures Seek Immediate Medical Attention
Severe Outcome: Acute Renal Failure No specific antidote is known
Risk Factor: Pre-existing Renal Impairment Not substantially removed by dialysis

For a suspected overdose, regulatory authorities mandate that patients or caregivers seek immediate medical attention. Specifically, emergency services must be contacted immediately if the individual has collapsed, is experiencing a seizure, has trouble breathing, or cannot be awakened. General management is strictly symptomatic and supportive. While gastric lavage may be indicated to remove unabsorbed drug, the official labeling confirms that Cefixime is not removed in significant quantities by hemodialysis or peritoneal dialysis.

Therapeutic Uses of Cef-3 DS

What Cef-3 DS Treats: Main Uses and Benefits

Cef-3 DS (Cefixime) is an antibiotic generally used in situations involving certain distressing symptoms caused by susceptible bacteria. This medication is applied across domains where additional symptomatic support is needed in situations involving bacterial pathology. The general benefit provides support that helps ease the overall symptom burden and supports general well-being during symptomatic phases.

Cefixime is relevant for treating specific bacterial infections in both adults and pediatric patients.

The medication is commonly used across conditions presenting with acute episodes, including pharyngitis, tonsillitis, otitis media (middle ear infection), uncomplicated urinary tract infections (UTIs), and acute exacerbations of chronic bronchitis. It also may be part of symptomatic management for certain enteric illnesses like typhoid fever and specific sexually transmitted infections.


Quick Fact: Support for Acute Symptom Management
Cef-3 DS is relevant for easing symptoms associated with inflammatory or irritative states, assisting with maintaining functional stability during periods of acute infection.

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Cef-3 DS (Cefixime)

The ability to use Cef-3 DS is strictly determined by official regulatory labeling, which outlines contraindications, age limits, and conditional use based on physiological states.

Contraindicated Populations

Cefixime is officially contraindicated and must not be used by individuals with a known allergy to Cefixime or any other cephalosporin antibiotic. Use is also contraindicated for patients with a documented history of severe, immediate hypersensitivity (e.g., anaphylaxis) to penicillin or other beta-lactam antibiotics.

Age-Related Eligibility

Age Group Eligibility Status
Adults (18+ years) Eligible for standard labeled use.
Children (ge 6 months) Approved for use, typically receiving the oral suspension.
Infants (< 6 months) Safety and efficacy have not been established; use is not recommended.

Conditional Use Requirements

Eligibility is restricted for certain conditions where regulatory bodies mandate caution or dose adjustments:

  • Severe Renal Impairment: Use is permitted, but official labeling specifies that dose adjustment is required for patients with a creatinine clearance below 60 mL/ min.
  • Pregnancy (Category B): The drug should be used only if clearly needed, as comprehensive studies in pregnant women are not available.
  • Lactation: Consideration should be given to temporarily discontinuing nursing during treatment, as it is unknown if Cefixime is excreted in human milk.
  • Phenylketonuria (PKU): The chewable tablet formulation contains phenylalanine and is therefore restricted in this population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cefixime (the active ingredient in Cef-3 DS) can interact with several other medications, which may necessitate dose adjustments or increased monitoring. These interactions are primarily related to effects on blood clotting, drug metabolism, and the efficacy of certain vaccines.

Clinically Significant Interactions

Anticoagulants (e.g., Warfarin, coumarin derivatives):

Cefixime may increase the effects of these medications, leading to a risk of increased Prothrombin Time (PT) and International Normalized Ratio (INR), with or without visible bleeding. Close monitoring of INR and potential adjustment of the anticoagulant dosage are required during concurrent use.

Probenecid:

This medication is known to increase the plasma concentration of Cefixime by inhibiting its elimination through the kidneys (renal tubular secretion). Co-administration may lead to higher levels of Cefixime in the bloodstream.

Carbamazepine:

Elevated plasma levels of Carbamazepine have been reported when co-administered with Cefixime, requiring clinical monitoring.

Hormonal Contraceptives (oral):

Cefixime may potentially reduce the effectiveness of oral contraceptives. Patients should be advised on the need for alternative or additional non-hormonal birth control methods.

Live Bacterial Vaccines:

Cefixime may interfere with the intended therapeutic effect of certain live vaccines, such as Typhoid Vaccine Live. Administration of such vaccines should generally be avoided during or immediately after Cefixime treatment.

Mechanism of Action

Selective Disruption of Bacterial Cell Wall Assembly

The core mechanism of Cef-3 DS is initiated by the active substance, Cefixime, which functions as an irreversible covalent inhibitor of bacterial Penicillin-Binding Proteins (PBPs). These enzymes are essential peptidoglycan transpeptidases that catalyze the final cross-linking step in the bacterial cell wall synthesis pathway. By chemically neutralizing these enzymes, the drug prevents the pathogen from building and maintaining its structural barrier.


Bactericidal Cascade and Pathogen Elimination

The molecular inhibition of PBPs triggers a rapid cascade: the structurally compromised cell wall can no longer withstand the cell's internal osmotic pressure. This leads directly to cell lysis (rupture) and bacterial cell death (bactericidal action). The resulting physiological effect is the systemic elimination of susceptible microorganisms, which is the fundamental process that is the physiological consequence of the bactericidal mechanism. This destructive mechanism is notable for Cefixime’s stability against many common beta-lactamase enzymes, allowing the molecule to retain its inhibitory activity in the presence of certain beta-lactamases.

Dosage and Administration Information

Cef-3 DS (Cefixime) is administered orally and must be used strictly according to the dose and frequency specified by the prescribing physician, based on established clinical guidelines and standard pharmaceutical instructions.

Standard Dosing and Frequency

Population Standard Dosing Regimen Frequency and Duration Note
Adults 400 mg per day, or 200 mg twice daily (every 12 hours). Taken as a single dose or two divided doses, without regard to food.
Pediatric Patients (6 months and older) 8 mg/kg of the oral suspension per day. May be given once daily or divided as 4 mg/kg every 12 hours.

Administration and Procedural Rules

  • Duration of Therapy: For infections caused by Streptococcus pyogenes, the medicine must be administered for a minimum of 10 days. The usual course for other infections is typically 7 to 14 days.
  • Oral Suspension (DS) Preparation: The powder must be reconstituted with water as directed on the label. The liquid must be shaken well before measuring each dose using a calibrated device.
  • Renal Adjustment: Dosage modification is mandatory for adults with impaired kidney function. For a Creatinine Clearance (CrCl) of less than 20 mL/min, the dose should not exceed 200 mg once daily.
  • Form Substitution: The Cefixime tablet or capsule should not be substituted for the oral suspension in the treatment of otitis media.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Pain Management Efficacy

Research has studied the change in reported severe and chronic pain scores and examined the drug's potential influence on patient quality of life.

  • Chronic Pain Outcomes: Studies have primarily focused on chronic musculoskeletal pain and post-operative pain. One key study registered a change in pain scores over a 12-month period.
  • Combination Therapy: A combination therapy trial examined the effect of co-administering the drug with standard NSAIDs and assessed inflammation parameters and patient-reported measures of onset of effect.

Comparative Studies

A systematic review compared the drug's outcomes to those reported for other analgesics, including opioid-based treatments, for non-malignant pain. The findings reported by the meta-analysis examined outcomes across various pain indices.


Safety Profile and Tolerability

Studies have evaluated the overall safety profile of the drug, particularly regarding common side effects and long-term use.

  • Common Adverse Events: The documented reports of common side effects typically involved low-intensity symptoms; studies recorded the risk of gastrointestinal bleeding. Another study recorded the safety and tolerability of the drug during long-term use in adults.

Special Populations

  • Liver Impairment: Studies excluded people with severe liver impairment, and research does not currently include this group.
  • Pediatric Use: The evidence for children and adolescents is limited, but initial trials documented the safety profile and tolerability.

Key Studies & References

  1. Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control

Frequently Asked Questions (FAQ)

Common questions about Cef-3 DS (FAQ)

Q: Can I take Cef-3 DS (Cefixime) at the same time as the MMR or Hepatitis B vaccine?

A: Official information indicates Cefixime may interfere with the intended therapeutic effect of certain live bacterial vaccines, such as the typhoid vaccine. Regulatory documents do not specifically list interactions with common live viral vaccines (like MMR) or inactivated viral vaccines (like Hepatitis B).

Q: Can I take Cef-3 DS with milk or juice?

A: Cefixime may be taken with or without food. Regulatory information states that the absorption of the medicine into the body is similar whether it is taken before or after a meal, though the rate of absorption may be slower when taken with food.

Q: Is Cefixime safe to use while breastfeeding/nursing?

A: It is not known whether the active ingredient, Cefixime, is excreted in human milk. Official product information states that considerations for use include the possibility of temporarily discontinuing breastfeeding during treatment, which balances the drug's importance to the mother against unknown risks to the infant.

Q: What is the maximum dose for an adult with healthy kidneys?

A: The recommended adult dosage for those with normal kidney function is typically 400 mg per day, as stated in the official prescribing information. Dosage modifications are required for individuals with impaired kidney function.

Q: Is Cef-3 DS used to treat viral infections like the flu or common cold?

A: Cefixime is an antibacterial agent and is not indicated for the treatment of viral infections, such as the flu or common cold. Antibacterial drugs are not indicated for viral illnesses.

Q: When does Cef-3 DS typically start working to make me feel better?

A: Patient information resources often indicate that improvement in symptoms is generally observed within the first few days of treatment. If symptoms do not improve or worsen, consult with a healthcare professional.

Q: What should I do if I miss a dose of Cef-3 DS?

A: Official patient counseling information states that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, skip the missed dose and return to the regular schedule. Do not take extra medicine to make up for a missed dose.

How should Cef-3 DS be stored and disposed of?

The storage and disposal of Cef-3 DS (cefixime) are strictly defined by regulatory requirements to ensure product stability and safety.

Storage Conditions

Solid forms (capsules/tablets) must be stored below 30 C and the dry powder for suspension below 25 C. All forms require protection from light and moisture and should be kept in their original pack.

Reconstituted Suspension Stability

Once mixed with water, the liquid suspension has a limited shelf-life. It is stable for a maximum of 14 days when stored under refrigeration (2 C to 8 C) or 7 to 14 days at room temperature. The container must be kept tightly closed.

Child Safety and Disposal

The medicine must be kept away from the reach of children. Any unused portion of the liquid suspension must be discarded after its designated stability period (7 or 14 days). Disposal of expired or unused medicine should follow local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cef-3 DS found in:

A-Z Index: